NewSquare Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

NewSquare Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4	Closed	-$408	–	936
2023 Q2	$408	Hold	4	–	–	﹤0.01%	703
2023 Q1	$364	Hold	4	–	–	﹤0.01%	739
2022 Q4	$152	Buy	+4	New	+$138	﹤0.01%	753

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

NewSquare Capital's RETA Position: Q3 2023 in Review

NewSquare Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 4 shares — an estimated $408 sold.

NewSquare Capital first reported a position in RETA in Q4 2022 and held it in 3 quarters. The position peaked at $408 in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

NewSquare Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
NewSquare Capital sold 4 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $408.
NewSquare Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 3 quarters.
NewSquare Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $408 in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.